Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer

<b>Introduction:</b> Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones. This study aimed to describe the clinical characteristics and outcomes of patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Colleen Mackenzie, Jasna Deluce, Morgan Black, Emma Churchman, Eric Winquist, Scott Ernst, David T. Laidley, Matthew Parezanovic, Kylea Potvin, Ricardo Fernandes
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Current Oncology
Subjects:
castration-resistant prostate cancer
radium-223
clinical outcomes
bone metastasis
Online Access:https://www.mdpi.com/1718-7729/31/11/480
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/31/11/480

Similar Items